Application and risk prediction of thrombolytic therapy in cardio-cerebrovascular diseases: a review

Author:

Zhang Kexin,Jiang Yao,Zeng Hesong,Zhu Hongling

Abstract

AbstractCardiocerebrovascular diseases (CVDs) are the leading cause of death worldwide, consuming huge healthcare budget. For CVD patients, the prompt assessment and appropriate administration is the crux to save life and improve prognosis. Thrombolytic therapy, as a non-invasive approach to achieve recanalization, is the basic component of CVD treatment. Still, there are risks that limits its application. The objective of this review is to give an introduction on the utilization of thrombolytic therapy in cardiocerebrovascular blockage diseases, including coronary heart disease and ischemic stroke, and to review the development in risk assessment of thrombolytic therapy, comparing the performance of traditional scales and novel artificial intelligence-based risk assessment models.

Funder

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Reference92 articles.

1. World Health Organization. Cardiovascular diseases (CVDs). Published June 3, 2022. Accessed 3 Jun 2022. https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1.

2. Cardiovascular diseases (CVDs). World Health Organization. 2022. https://www.who.int/news-room/factsheets/detail/cardiovascular-diseases-(cvds).

3. Phipps MS, Cronin CA. Management of acute ischemic stroke. BMJ. 2020;368. https://doi.org/10.1136/bmj.l6983.

4. Musuka TD, Wilton SB, Traboulsi M, Hill MD. Diagnosis and management of acute ischemic stroke: Speed is critical. CMAJ. 2015;187(12):887–93. https://doi.org/10.1503/cmaj.140355.

5. Proctor P, Leesar MA, Chatterjee A. Thrombolytic Therapy in the Current ERA: Myocardial Infarction and Beyond. Curr Pharm Des. 2017;24(4). https://doi.org/10.2174/1381612824666171227211623.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3